Compounded Semaglutide Cost vs Brand GLP-1: 2026 Price Breakdown

The compounded semaglutide cost historically ran roughly $150–$300 per month, versus $1,000–$1,350 list for brand Ozempic or Wegovy. But after the FDA declared the semaglutide and tirzepatide shortages resolved in 2025, large-scale compounding of these GLP-1 drugs is now largely prohibited, narrowing the cheaper compounded route considerably.

Compounded vs brand GLP-1 at a glance (2026)

• Brand Ozempic (semaglutide) list price: ~$997.58/month [VERIFY: current Novo Nordisk list price]
• Brand Wegovy (semaglutide) list price: ~$1,349.02/month [VERIFY: current Novo Nordisk list price]
• Brand Zepbound (tirzepatide) list price: ~$1,086/month; self-pay vials lower [VERIFY: current Lilly pricing]
• Manufacturer cash/self-pay programs: roughly $199–$499/month depending on drug, dose, and timing
• Compounded semaglutide (when historically available): ~$150–$300/month
• FDA status: semaglutide and tirzepatide shortages resolved; routine compounding of both is now restricted
• Best-studied for: weight management and type 2 diabetes (large human trials)

What is the difference between compounded and brand GLP-1?

Brand GLP-1 medications are FDA-approved, mass-manufactured products: Ozempic and Wegovy (semaglutide) from Novo Nordisk, and Mounjaro and Zepbound (tirzepatide) from Eli Lilly. Each has been through FDA review for safety, effectiveness, and manufacturing quality, and each carries a fixed-dose pen or vial with a printed label.

Compounded GLP-1 products are mixed by a pharmacy for an individual patient rather than mass-produced by the drugmaker. Under U.S. law, two pathways exist: 503A state-licensed compounding pharmacies (which compound patient-specific prescriptions) and 503B outsourcing facilities (which can compound larger batches under stricter quality rules). Compounded drugs are not FDA-approved and are not reviewed for safety or effectiveness before sale.

The price gap that drove compounded GLP-1 demand was large: compounded semaglutide commonly ran about $150–$300 per month through telehealth providers, while brand list prices sat near $1,000–$1,350. That gap, however, existed largely because of a temporary drug-shortage allowance — which has now changed. (For background on how these drugs work, see our semaglutide complete guide.)

How much does compounded semaglutide cost in 2026?

When widely available during the 2023–2025 shortage, compounded semaglutide typically cost $150–$300 per month through telehealth platforms, often bundled with a provider visit. Some programs advertised introductory pricing under $200. These figures are marketing-reported ranges, not regulated list prices, and varied by dose, pharmacy, and bundled services [VERIFY: specific compounded telehealth price ranges, 2026].

The critical 2026 context: the FDA determined the semaglutide injection shortage resolved and set enforcement-discretion end dates of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities, after which routine compounding of semaglutide from bulk substance was no longer permitted (FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize," 2025). Tirzepatide reached its shortage-resolution and enforcement milestones earlier, in early 2025.

This means the cheap, easily-accessible compounded semaglutide of 2024 is largely off the table for most patients in 2026. Limited exceptions exist — for example, a patient-specific clinical need such as a documented allergy to an inactive ingredient in the approved product — but these are narrow and require a prescriber's justification. Consult your healthcare provider and pharmacist about whether any compounded option is lawfully available for your situation; legal status varies by jurisdiction, so consult a lawyer for binding advice.

How much does brand-name GLP-1 cost?

Brand list prices remain the highest sticker figures, though almost no cash patient pays full list. Reported 2026 manufacturer list prices include:

All figures are approximate, drawn from manufacturer-reported list prices, and may have changed; verify current pricing directly with the manufacturer or pharmacy [VERIFY: 2026 list prices for each brand].

List price is rarely what you pay. With commercial insurance plus a manufacturer savings card, eligible patients have paid as little as $25/month for covered prescriptions. Without insurance, the bigger story in 2025–2026 has been direct manufacturer cash channels: Novo Nordisk's NovoCare and Eli Lilly's LillyDirect now sell self-pay GLP-1s well below list. Reported self-pay figures have ranged from roughly $199 to $499 per month depending on the drug, dose, and any limited-time promotion [VERIFY: current NovoCare and LillyDirect self-pay prices and promotion end dates]. Novo Nordisk has also announced further list-price reductions taking effect in 2027 [VERIFY: 2027 list-price reduction details].

For dosing-specific guidance, see our semaglutide complete guide and tirzepatide protocol guide; do not change your regimen based on price alone.

Is the brand drug worth the higher price?

The clinical evidence base sits almost entirely behind the brand products, because the large trials studied the FDA-approved formulations.

In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% for placebo, in adults with overweight or obesity without diabetes (Wilding et al., 2021, N Engl J Med). For tirzepatide, the SURMOUNT-1 trial reported mean weight reductions of 15.0%, 19.5%, and 20.9% at the 5-mg, 10-mg, and 15-mg doses respectively at 72 weeks, versus 3.1% for placebo (Jastreboff et al., 2022, N Engl J Med).

Beyond weight, the brand semaglutide evidence base extends to cardiovascular outcomes. In the SELECT trial of 17,604 adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% versus placebo over a mean 40 months (Lincoff et al., 2023, N Engl J Med). Head-to-head data also distinguish the two molecules: in the SURMOUNT-5 trial, tirzepatide produced significantly greater mean weight reduction than semaglutide at 72 weeks in adults with obesity without diabetes (Aronne et al., 2025, N Engl J Med). And the formulation matters for efficacy comparisons — the STEP 8 trial found once-weekly semaglutide produced greater weight loss at 68 weeks than once-daily liraglutide (Rubino et al., 2022, JAMA). None of these outcome trials studied compounded copies, so their results cannot be assumed to transfer to a non-FDA-reviewed compounded product.

These outcomes reflect the approved, standardized products — known active ingredient, known concentration, known purity. Compounded versions are not FDA-reviewed, and their content can vary. The FDA has noted that some compounders used salt forms of semaglutide (semaglutide sodium, semaglutide acetate) that differ from the base ingredient in approved drugs and for which the agency is "not aware of any lawful basis" for use in compounding (FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss"). Whether a cheaper compounded product delivers the same result as the trial-validated brand is not something the trial data can answer. Consult your healthcare provider.

What are the safety and quality trade-offs of compounded GLP-1?

Price is only one axis; safety and quality are the other. The FDA has flagged several specific concerns with compounded GLP-1 products that buyers weighing the cost savings should understand.

Dosing errors. The FDA issued an alert on July 26, 2024 about adverse events — some requiring hospitalization — linked to dosing errors with compounded injectable semaglutide. Errors arose from patients drawing and self-injecting from multi-dose vials and from confusion between milligrams, milliliters, and "units," as well as provider miscalculations (FDA, "FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products," 2024).

Unverified ingredients. Because compounded products bypass FDA pre-market review, the agency warns they "may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether," and has acted against illegally imported GLP-1 active ingredients from unverified foreign sources (FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss").

Brand products carry their own well-documented side effects — predominantly gastrointestinal (nausea, vomiting, diarrhea) — but they come with verified content and a fixed-dose delivery device that reduces measurement error. Whichever route a person considers, GLP-1 therapy requires medical supervision. Consult your healthcare provider before starting, stopping, or changing any GLP-1 protocol, and review our BPC-157 complete guide for how we assess peptide sourcing and quality before evaluating any non-pharmacy source.

What does the FDA's 2026 compounding rule change mean for cost?

The economics of the "cheap GLP-1" era were built on the drug-shortage exception. While a drug is on the FDA shortage list, compounders may make copies; once the shortage resolves, that allowance ends.

Both semaglutide and tirzepatide came off the FDA shortage list in 2025, ending the broad compounding window. Then, on April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating it "did not identify a clinical need" for outsourcing facilities to compound these drugs from bulk substance (FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List," April 30, 2026). The proposal carried a public-comment period [VERIFY: exact comment deadline, reported as on or around June 29, 2026].

For consumers, the practical effect is that the lawful low-cost compounded route has narrowed sharply, while manufacturers have simultaneously cut cash prices through NovoCare and LillyDirect. The price gap between "compounded" and "brand" has compressed: the relevant 2026 comparison for most people is no longer compounded-vs-list-price, but manufacturer self-pay vs insurance copay. Note: these GLP-1 drugs are FDA-approved medicines on a separate regulatory track from the research peptides (such as BPC-157 and TB-500) under review at the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting; the PCAC peptide reclassification process does not govern semaglutide or tirzepatide pricing.

Frequently asked questions

Q: How much does compounded semaglutide cost in 2026? A: When available during the 2023–2025 shortage, compounded semaglutide commonly cost about $150–$300 per month through telehealth providers, often bundled with a clinician visit. These were marketing-reported ranges, not regulated prices. In 2026, the broad availability that drove those low prices has largely ended, because the FDA declared the semaglutide shortage resolved and restricted routine compounding. Cheap compounded semaglutide is no longer freely accessible to most patients. Verify any current pricing and lawful availability with a licensed pharmacist, and consult your healthcare provider.

Q: Why is compounded GLP-1 harder to get now? A: U.S. law lets compounding pharmacies make copies of a drug mainly while it is on the FDA shortage list. The FDA determined both the semaglutide and tirzepatide shortages were resolved in 2025, with enforcement-discretion end dates in spring 2025 (April 22 for 503A pharmacies and May 22 for 503B facilities for semaglutide). In April 2026 the FDA further proposed removing these drugs from the 503B bulks list. Narrow patient-specific exceptions may remain, but routine large-scale compounding is now restricted. Consult your provider and pharmacist.

Q: Is brand Wegovy or Ozempic cheaper if I pay cash? A: List prices are high (roughly $997.58 for Ozempic and $1,349.02 for Wegovy, per manufacturer-reported figures), but few cash patients pay list. Novo Nordisk's NovoCare and Eli Lilly's LillyDirect now offer direct self-pay pricing reported in the $199–$499/month range depending on drug, dose, and promotion. With insurance plus a savings card, eligible patients have paid as little as $25/month. Verify current pricing directly with the manufacturer.

Q: Is compounded semaglutide the same as brand semaglutide? A: Not necessarily. Compounded products are not FDA-approved and are not reviewed for safety, effectiveness, or quality before sale. The FDA has reported that some compounders used salt forms (semaglutide sodium or acetate) that differ from the base ingredient in approved drugs, and warns compounded versions may vary in content or be contaminated. The large efficacy trials (STEP 1, SURMOUNT-1) studied the approved brand formulations, not compounded copies. Consult your healthcare provider.

Q: How effective are brand GLP-1 drugs for weight loss? A: In the STEP 1 trial, semaglutide 2.4 mg produced a mean 14.9% body-weight reduction at 68 weeks versus 2.4% for placebo (Wilding et al., 2021, NEJM). In SURMOUNT-1, tirzepatide produced mean reductions of 15.0%, 19.5%, and 20.9% at the 5-, 10-, and 15-mg doses at 72 weeks versus 3.1% for placebo (Jastreboff et al., 2022, NEJM). These figures reflect the approved products combined with lifestyle intervention. Individual results vary; discuss expectations with a healthcare provider.

Q: Is it legal to buy compounded GLP-1 from a telehealth company? A: It depends on the specifics and the date. Routine compounding of semaglutide and tirzepatide is now restricted because the shortages are resolved, though narrow patient-specific exceptions can apply. Many telehealth sources also sell "research" or non-pharmacy GLP-1 products that are not lawful for human use. Legal status varies by state and changes frequently; consult a lawyer for binding advice and a licensed provider before using any product.

Q: Will brand GLP-1 prices keep falling? A: Possibly. Manufacturers have expanded direct cash-pay channels (NovoCare, LillyDirect) and Novo Nordisk has announced further list-price reductions slated for 2027 [VERIFY: 2027 reduction details]. Competition, new oral formulations, and policy changes could push prices lower. But pricing shifts frequently, so confirm the current figure with the manufacturer or your pharmacy rather than relying on any single published number.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
3. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
4. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
6. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/
8. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
9. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. PMID: 35015037. https://pubmed.ncbi.nlm.nih.gov/35015037/
10. U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (FDA decision memorandum). February 21, 2025. https://www.fda.gov/media/185526/download